Form D · Biotechnology
Echo Therapeutics, Inc.
Iselin, NJ · CIK 0001031927
Offering snapshot reported Feb 8, 2016 · SEC filing
- Reported sold
- $1.79M Offering amount: $6M
- Investors reported
- 15 Form D · investor count
- Minimum accepted
- $50K Reported outside-investor minimum
- First sale
- Jan 29, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 8, 2016 | Initial | $1,787,000 | No comparison | 15 | SEC filing |
| Dec 19, 2013 | Initial | $10,000,000 | No comparison | 4 | SEC filing |
| Feb 15, 2011 | Amendment | $2,896,500 | No comparison | 46 | SEC filing |
| Feb 15, 2011 | Initial | $3,506,000 | No comparison | 3 | SEC filing |
| Nov 5, 2010 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Oct 21, 2010 | Initial | $2,455,126 | No comparison | 38 | SEC filing |
| Dec 7, 2009 | Initial | $562,500 | No comparison | 9 | SEC filing |
| Nov 20, 2009 | Initial | $3,011,320 | No comparison | 8 | SEC filing |
| Jul 28, 2009 | Initial | $2,006,031 | No comparison | 1 | SEC filing |
| Apr 2, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Feb 25, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jun 25, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Feb 12, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Oct 2, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Mar 21, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $146K (estimated)
- Finders' fees
- $0
- Form D file number
- 021-256938
+ 8% warrants
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Newbridge Securities Corporation | 104065 |
Source: Form D, filed Feb 8, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kimberly Burke | Executive |
| Robert Doman | Director, Executive |
| Elazer R. Edelman | Director |
| Vincent Enright | Director |
| Shepard M. Goldberg | Director |
| Michael M. Goldberg | Director |
| William Grieco | Director |
| Scott W. Hollander | Director, Executive |
| Robert Langer | Director |
| Harry Mitchell | Executive |
| Patrick Mooney | Director, Executive |
| Christopher Schnittker | Executive |
| Alan W. Schoenbart | Executive |
| Shawn Singh | Director |
| James Smith | Director |
| Walter Witoshkin | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
99 Wood Avenue South Suite 302
Iselin, NJ, 08830
Iselin, NJ, 08830